DV
Dividend Vision

RLYB — Rallybio Corporation

Rallybio Corporation (RLYB)

Total return is -84.9% over the past 5 years, 173.4 points behind SPY at 88.5%. Its deepest 1-year drawdown was 31.1%.

Rallybio Corporation is a healthcare equity stock that operates as a clinical-stage biopharmaceutical company focused on developing treatments for rare and severe genetic disorders. The security does not currently offer dividend distributions or a meaningful yield profile, as the company prioritizes reinvestment of capital into research and development. This holding appeals primarily to growth-oriented investors with risk tolerance for early-stage biotech ventures rather than those seeking current income.

RLYB key facts

Asset type
Stock
Asset class
Equity
Inception date
07/29/2021
Distribution frequency
None
Last close
$16.99
Market cap
$90,225,376
Average volume
12900.0
Beta
-0.857
Payout ratio
0.0
P/E ratio
2.1106
Forward P/E
0.0
EPS
$8.05